Posted by Michael Wonder on 04 May 2022
Phathom Pharmaceuticals announces FDA approval of Voquenza Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquenza Dual Pak (vonoprazan, amoxicillin) for the treatment of H. pylori infection in adults
3 May 2022 - U.S. commercial launch anticipated in the third quarter of 2022.
Phathom Pharmaceuticals announced today the U.S. FDA approved both Voquenza Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquenza Dual Pak (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori infection in adults.
